Figure_S2 from Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors
Elliott J. Brea(Dana-Farber Cancer Institute), Eric L. Smith(Dana-Farber Cancer Institute), Ha Vo(Dana-Farber Cancer Institute), Brittaney A. Leeper(Dana-Farber Cancer Institute), Timothy J. Haggerty(Dana-Farber Cancer Institute), Changjing Deng(Combat Capabilities Development Command Soldier Center), Marco Campisi(Dana-Farber Cancer Institute), Louis L. Liu(Combat Capabilities Development Command Soldier Center), Kenneth Ngo(Brooks Rehabilitation Clinical Research Center), Malcolm Holterhus(Dana-Farber Cancer Institute), Sachiv Chakravarti(Johns Hopkins University), Xiaoxiao Wang(Combat Capabilities Development Command Soldier Center), Pasi A. Jänne(Harvard University), Thanh U. Barbie(Brigham and Women's Hospital), Aisha Saldanha(Dana-Farber Cancer Institute), Anusuya Ramasubramanian(Dana-Farber Cancer Institute), Cloud P. Paweletz(Massachusetts General Hospital), Tran C. Thai(Dana-Farber Cancer Institute), David A. Barbie(Dana-Farber Cancer Institute), Elena V. Ivanova(Massachusetts General Hospital), Simon Baldacci(Dana-Farber Cancer Institute), Prafulla C. Gokhale(Harvard University), Navin R. Mahadevan(Brigham and Women's Hospital), Marie-Anaïs Locquet(Dana-Farber Cancer Institute), Neil Savage(Unknown), Bishma Tuladhar(Dana-Farber Cancer Institute), Suthakar Ganapathy(Northeastern University), Cui Nie(Combat Capabilities Development Command Soldier Center), Abdulmajeed Salamah(Dana-Farber Cancer Institute), Carla Stornante(Dana-Farber Cancer Institute), Alexis Mottram(Dana-Farber Cancer Institute), Conor Hinchey(Dana-Farber Cancer Institute), Evelyn B. Mesler(Dana-Farber Cancer Institute), Zehua Li(Dana-Farber Cancer Institute), Martina De Vizio(Dana-Farber Cancer Institute), Francesco Facchinetti(Inserm)
Cited by 0
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
|Nature|2009|4.2k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k